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Summary
We present a case of a 57-year-old man who presented 
with progressive cerebellar dysarthria and cerebellar 
ataxia. Additional investigations confirmed the 
diagnosis of progressive multifocal leukoencephalopathy 
(PML) in the posterior fossa. This is a demyelinating 
disease of the central nervous system, caused by an 
opportunistic infection with John Cunningham virus. 
PML has previously been considered a lethal condition, 
but because of careful monitoring of patients with 
HIV and of patients using immunosuppressive drugs 
it is discovered in earlier stages and prognosis can 
be improved. Our patient had no known immune-
compromising state, but further work-up revealed that 
the PML was most likely the first presentation of a 
previous untreated autoimmune disorder: sarcoidosis.
Background
Progressive multifocal leukoencephalopathy (PML) 
is a life-threatening demyelinating disease of the 
central nervous system (CNS) caused by a viral 
infection, usually encountered in immune-compro-
mised patients.1 With this case, we illustrate that 
physicians should also be aware of PML in suppos-
edly immune-competent patients.
caSe preSentation
A 57-year-old man presented at a regional hospital 
with a 3-month history of gradually worsening of 
articulation and right-sided coordination problems. 
His medical history mentioned Raynaud phenom-
enon and transient muscle complaints with spon-
taneous normalised positive antinuclear antibodies 
(ANA) 15 years ago. Neurological examination 
revealed a cerebellar dysarthria and ataxia of his 
right arm and leg.
inveStigationS
MRI scanning of the brain showed non-specific 
white matter lesions in both cerebellar hemispheres, 
without contrast enhancement or diffusion restric-
tion. Routine blood serum and cerebrospinal fluid 
(CSF) examinations were normal. ANA and extract-
able nuclear antigens (ENA) were increased; the 
antineutrophil cytoplasmic antibodies were nega-
tive. The patient clinically deteriorated during the 
following week and was referred to our university 
hospital for further work-up. Repeated CSF exam-
ination showed a mild mononuclear pleocytosis 
of 19 cells/mm3. Repeated brain MRI (figure 1) 
showed progressive white matter lesions (hyper-
intense on fluid-attenuated inversion recovery 
(FLAIR) and T2-weighted images and hypointense 
on T1-weighted images) displaying subtle periph-
eral diffusion restriction. Serum serological tests 
for Lyme disease, syphilis and HIV were negative. 
Additional laboratory findings showed a low CD4 
count (0.24×109/L) and the angiotensin-converting 
enzyme (ACE) in serum was minimally increased 
(54 U/L). CSF cytology and PCR for cytomegalo-
virus, herpes zoster and herpes simplex virus 1 and 
2 were negative. Paraneoplastic antibodies were also 
negative. Eventually, PCR for John Cunningham 
virus (JC virus) was positive in the CSF. Finally, 
a whole-body [18F]fluorodeoxyglucose positron 
emission tomography (PET)–CT showed symmetric 
mediastinal and hilar lymphadenopathy with 
increased tracer uptake, consistent with sarcoidosis.
differential diagnoSiS
Initial differential diagnostic thoughts were among 
others opportunistic viral infections, acute dissem-
inated encephalomyelitis (ADEM) and neuro-
sarcoidosis. But imaging findings were not fully 
consistent with both ADEM and neurosarcoidosis.
Finally, the positive PCR for JC virus, combined 
with clinical and radiological features, made a clear 
diagnosis: PML.1 Further work-up made an under-
lying autoimmune disease plausible.
outcome and follow-up
Our patient deteriorated fast suffering from progres-
sive ataxia of both arms and legs, severe dysarthria, 
swallowing difficulties, behavioural changes and 
depression. He declined any further diagnostic 
work-up; therefore, histopathological evidence of 
a suspected underlying immune-suppressive disease 
is not available. Treatment with mirtazapine was 
started, unfortunately without any measurable clin-
ical improvement. The patient died about 2 months 
after first presentation. We obtained no obduction.
diScuSSion
PML is a demyelinating disease and a rare compli-
cation of an opportunistic JC virus infection; a 
polyomavirus that infects >50% of the world’s 
population.1 Clinical symptoms depend on the loca-
tion of demyelination of the CNS. Most common 
locations are the frontal or parieto-occipital 
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unusual presentation of more common disease/injury
regions; only 1 out of 10 patients has brainstem or cerebellar 
lesions.1 2 However, in patients with HIV/AIDS, cerebellar 
localisation of PML lesions seems to be less rare: about 34%.3 
MRI scanning is an important diagnostic tool to identify PML. 
FLAIR images have the highest sensitivity showing hyperin-
tense lesions. Lesions are hyperintense on T2 sequences too and 
hypointense on T1 sequences. Only 15%–40% of cases show 
contrast enhancement and also diffusion restriction may occur 
on diffusion-weighted images.1 4 Currently, definite PML can be 
diagnosed considering the triad of compatible clinical features, 
compatible imaging findings and positive CSF PCR for JC virus. 
A brain biopsy is not obligatory for the diagnosis.1
PML is a disease mostly seen in immune-compromised 
patients. It is traditionally associated with HIV or AIDS, but 
in the past decades there has been a shift to medication-asso-
ciated PML with the increasing use of immune-compromising 
medication. Also, long-standing inflammatory disorders (eg 
sarcoidosis, systemic lupus erythematosus) seem to be related 
with developing PML.1 5–7 Using MRI as a screening tool for 
early detection of PML is suggested in some of these patient 
groups.8 Current treatment consists of withdrawal of the caus-
ative immune-compromising agent, treatment of the underlying 
disease and supportive care. PML used to be a lethal condition, 
but nowadays mortality and functional outcome depend more 
and more on the underlying condition and PML stage at time 
of diagnosis.7 9 Different small trials suggest cidofovir, acyclovir, 
cytarabine, chlorpromazine, mefloquine, mirtazapine or inter-
leukin-7 as treatment options.4 10 Some of these seem to give a 
favourable outcome, but they are not yet proven to cure or end 
disease progression.4
Our case shows a relatively rare presentation of PML in the 
posterior fossa structures in an initial supposedly immunocom-
petent patient. Our hypothesis is, however, that an untreated 
autoimmune disease has caused reactivation of the JC virus 
with PML as the presenting symptom. This is supported by the 
patient’s medical history and current mediastinal lymphadenop-
athy on PET–CT, low CD4 count and positive results of ENA 
and ANA in serum. This, combined with increased serum ACE, 
makes sarcoidosis our probable diagnosis. PML as a first presen-
tation of an inflammatory or autoimmune disorder is also rare, 
but there are a few other case reports concerning PML as a first 
presentation of sarcoidosis.5 11–13 We were not able to confirm 
the suspected diagnosis of sarcoidosis with histopathological 
findings in this case, which is our limitation.
Our case illustrates that PML needs to be considered as a differ-
ential diagnosis even if there is no known actual immune-com-
promising state. And when there is no obvious cause of PML, it 
is important to search for an underlying immunological disorder 
like an untreated autoimmune disease.
learning points
 ►  Progressive multifocal leukoencephalopathy (PML) can be 
diagnosed with the triad of compatible clinical features, 
compatible imaging findings and positive cerebrospinal 
fluid PCR for John Cunningham virus; a brain biopsy is not 
necessary.
 ►  Although relatively rare, PML can present in the posterior 
fossa structures.
 ►  Consider PML in your differential diagnosis, even when there 
is no known immune-compromising state.
 ►  When PML is diagnosed search for an underlying cause: 
typical causes ((untreated) HIV or the use of immune-
suppressive drugs) or atypical causes (unknown or untreated 
inflammatory/autoimmune disease).
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figure 1 Follow-up MRI of the brain. Transverse T2-weighted image, 
diffusion-weighted image (DWI) and corresponding apparent diffusion 
coefficient (ADC) map (left to right). Transverse T2-weighted image of 
the posterior fossa shows confluent hyperintense white matter changes 
in both cerebellar hemispheres. On the right more than left side, there 
is extension through the middle cerebellar peduncle into the brainstem. 
DWI depicts high signal in the periphery of the white matter lesions left 
more than right (arrowheads) with corresponding low signal on the ADC 
map (arrowheads), consistent with restricted diffusion. There was no 
contrast enhancement (not shown).
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